Quality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma
Helen Gogas(National and Kapodistrian University of Athens), Keith T. Flaherty(Cancer Research Center), Ivana Krajsová(Charles University), Ana Arance(Hospital Clínic de Barcelona), Mario Mandalà(University of Perugia), Gabriella Liszkay(National Institute of Oncology), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Jan Willem B. de Groot(Isala), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Dirk Schadendorf(National Center for Tumor Diseases), Laure A. De Parseval(Novartis (Switzerland)), Michael D. Pickard(Peter MacCallum Cancer Centre), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Carmen Loquai(Johannes Gutenberg University Mainz), Reinhard Dummer(University Hospital of Zurich), Caroline Robert(Institut Gustave Roussy), Claus Garbe(University of Tübingen), V. Sandor(Incyte (United States)), Naoya Yamazaki(Tokyo National Hospital)
Cited by 3
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k